3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase NA
1
Phase 3
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
558
Carcinoma, Non-Small-Cell Lung
514
Prostatic Neoplasms
336
Colorectal Neoplasms
273
Neoplasms
269
Multiple Myeloma
267
Leukemia, Myeloid, Acute
225
Squamous Cell Carcinoma of Head and Neck
217
Lung Neoplasms
210
Neoplasm Metastasis
205
Carcinoma, Hepatocellular
198
Melanoma
175
Triple Negative Breast Neoplasms
174
Pancreatic Neoplasms
171
Recurrence
153
Ovarian Neoplasms
152
Lymphoma
142
Glioblastoma
136
Brain Neoplasms
134
Sarcoma
131
Carcinoma, Renal Cell
128
Lymphoma, Large B-Cell, Diffuse
126
Leukemia, Lymphocytic, Chronic, B-Cell
126
Head and Neck Neoplasms
124
Stomach Neoplasms
123
Precursor Cell Lymphoblastic Leukemia-Lymphoma
110
Rectal Neoplasms
109
Myelodysplastic Syndromes
104
Uterine Cervical Neoplasms
100
Urinary Bladder Neoplasms
100
Interventions
relatlimab
1
pembrolizumab
1
Nivolumab
1
CP protocol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Male Urogenital Diseases
×
1 year
×
Clear all
NCT06353906
2025-12-08
PRIAM
The Netherlands Cancer Institute
Phase 2
Recruiting
27 enrolled
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled